* BioVant with new H1N1 vaccine gives 100 pct protection
* Plans to license BioVant to a vaccine maker
* Shares surge 28 pct (Adds company comments, updates share movement)
By Anand Basu
BANGALORE, Aug 17 (Reuters) - BioSante Pharmaceuticals Inc BPAX.O said its adjuvant, BioVant, increases the efficacy of vaccines for multiple flu strains, including a potential new vaccine against H1N1 virus, or swine flu, sending its shares up 28 percent.
An adjuvant is an ingredient that boosts the immune system response, which means that less active ingredient is needed in each dose.
BioSante is looking to license BioVant to a vaccine maker and expects to earn royalties from the adjuvant, senior Director of Operations Bill Milling said by phone.
“We have had some talks with some companies, but nothing has gone as far as being at the serious level yet,” Milling said.
The specialty pharmaceutical company said BioVant when used with a potential new vaccine against swine flu resulted in 100 percent protection from symptoms of illness, including weight loss and death in animal studies.
Swine and bird flu vaccines using BioVant may allow for availability of a greater number of lower-dose vaccines, the company said.
Shares of the company touched a high of $2.50 before paring some gains to trade up 25 cents at $2.21 Monday afternoon on Nasdaq. (Editing by Anne Pallivathuckal)